Navigation Links
Kinase test may yield big gains for drug-resistant cancers
Date:4/12/2012

Chapel Hill, NC In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.

Kinases are proteins expressed in human tissues that play a key role in cell growth, particularly in cancer. Of the 518 known human kinases, about 400 are expressed in cancers, but which ones and how many are actually active in tumors has been difficult to measure. Tremendous efforts have been made to develop kinase inhibitors as cancer treatments, which have resulted in key drugs such as Herceptin, Tykerb, and Gleevec. However, in spite of the effectiveness of this class of cancer drugs, most cancers eventually become resistant. The UNC team has developed a test that can measure both the presence and activity of 60-70 percent of all kinases simultaneously, allowing investigators to see how cancers evade treatment with kinase inhibitors so that they can combine drugs to block resistance.

Gary Johnson, PhD, the project's principal investigator, says, "Single-agent kinase inhibitors are promising in principle, but often fail in practice because the network of tumor kinases learns how to get around the inhibitor, leading to rapid drug resistance. We're very excited about the test our lab has developed because it works very well in a model of breast cancer to predict the success of combination therapies."

Johnson, who is the Kenan Distinguished Professor and chair of the department of pharmacology in the UNC School of Medicine and a member of UNC Lineberger Comprehensive Cancer Center, is working with UNC Breast Center medical director Lisa Carey, MD, UNC Lineberger director Shelley Earp, MD, and surgical oncologist Keith Amos, MD, to perform clinical trials using the technology with the goal of real-time, personalized therapies for breast cancer.

"One of the most frustrating things as an oncologist is when a patient's tumor develops resistance to a treatment," says Carey, who is also a member of UNC Lineberger. "We are excited about the ability to examine tumor samples before, during, and after kinase inhibitor treatment to see how the tumor kinase profile changes, and potentially respond to those changes using different inhibitors."

The team hopes to be able to track and define the kinase 'reprogramming' that takes place in tumors during therapy and to use the new test to identify combinations of drugs that will block the cancer's adaptive behavior that leads to drug resistance. A patent application has been filed for the testing technology.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Battlefield camaraderie yields long-term dividends for veterans, study finds
2. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
3. Gene Sequencing Yields Picture of Human Gut
4. HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference
5. Abbreviated Trials Yield Misleading Results: Study
6. H1N1 Virus Yields Up More Secrets
7. Safety and diagnosis yield of colonoscopy in Hong Kong Chinese children
8. Glued graft for Pterygium Yield Better Cosmetic Results
9. Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. In infant heart surgery, newer technique yields better survival in first year of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the ... healthy lifestyles and highlighting the importance of proactive eye and ear health. The ... the latest innovations in hearing aid technology. , In this issue, the ...
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has released a new publication this ... of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared to what ... historical woman. , “The world bows, kisses the feet of, cries out to and ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: